Genix Pharmaceuticals Corporation (TSXV:GENX)

Market Cap	1.53M
Revenue (ttm)	68.00
Net Income (ttm)	-88.76K
Shares Out	61.22M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,000
Average Volume	138,546
Open	0.0250
Previous Close	n/a
Day's Range	0.0250 - 0.0250
52-Week Range	0.0200 - 0.0600
Beta	0.38
RSI	43.75
Earnings Date	Feb 26, 2026

About Genix Pharmaceuticals

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to support kidney health; and Sucanon, a herbal health supplement to manage blood sugar levels and enhance insulin sensitivity in non-insulin dependent adults. It also markets and sells nutraceuticals and pharmaceutical products, su...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 4,000
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: GENX

Financial Performance

In 2024, Genix Pharmaceuticals's revenue was 4,051, a decrease of -67.19% compared to the previous year's 12,347. Losses were -73,196, -98.33% less than in 2023.